Skip to main content

Market Overview

Recap: Becton, Dickinson Q2 Earnings



Shares of Becton, Dickinson (NYSE:BDX) decreased 0.4% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share increased 25.10% year over year to $3.19, which beat the estimate of $3.04.

Revenue of $4,907,000,000 up by 15.38% year over year, which beat the estimate of $4,890,000,000.


The upcoming fiscal year's EPS expected to be between $12.75 and $12.85.

The upcoming fiscal year's revenue expected to be between $19,171,000,000 and $19,513,000,000.

Details Of The Call

Date: May 06, 2021

Time: 08:00 AM

ET Webcast URL:


52-week high: $284.97

52-week low: $219.50

Price action over last quarter: down 1.93%

Company Profile

Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.


Related Articles (BDX)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at